Senna Tablet
Natural health product licensed in Canada
- Other names
- Senna Laxative
- Licence holder
- LSL MedPlus Inc.
- NPN or DIN-HM
- 80086346
- Status
- Active licence
- Licence date
- 18 June 2018
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- TPD Cat IV/LS
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Sennoside A&B Source : Senna alexandria - feuilles | 8.6 milligramme | Not calculated |
| Sennoside A&B Source : Sennoside de calcium | 8.6 milligramme | Not calculated |
Non-medicinal ingredients
Hydroxypropyl méthylcellulose, Cellulose microcristalline, Stéarate de magnésium, Glycérine, Phosphate de calcium, dibasique, Croscarmellose de sodium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes et adolescents | minimum: 12 years | minimum: 2 Comprimé ; maximum: 4 Comprimé | minimum: 1 day ; maximum: 2 days |
Uses authorised in Canada
Stimulant Laxative. For relief of occasional constipation. Promotes bowel movement.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner if symptoms persist. Consult a health care practitioner if symptoms worsen; . Consult a health care practitioner prior to use: - if you are taking thiazide diuretics, corticosteroids, licorice root or other medications or health products which may aggravate electrolyte imbalance; - if you have a kidney disorder or are taking cardiac medications such as cardiac glycosides or antiarrhythmic medications. - if you have faecal impaction or symptoms such as abdominal pain, nausea, vomiting or fever. - if you are pregnant or breast-feeding. Reduce dose or discontinue use if you experience abdominal pain, cramps, spasms and/or diarrhoea.
- Effets indésirables connus
Hypersensitivity is known to occur, in which case, discontinue use.
- Contre-indications
Do not use if you have abnormal constrictions of the gastrointestinal tract, potential or existing intestinal blockage, atonic bowel, appendicitis, inflammatory colon disease such as Crohn's disease or ulcerative colitis, abdominal pain of unknown origin, undiagnosed rectal bleeding, severe dehydration with depleted water or electrolytes.
Source
Official Health Canada record, licence 80086346
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.